K2M shareholders approved the acquisition by Stryker, originally proposed Aug. 29.
Here are five things to know:
1. The shareholders approved the agreement and plan of merger, moving forward plans for the $1.4 billion acquisition.
2. K2M will be merged with Stryker subsidiary Merger Sub and become a wholly owned subsidiary of Stryker as well.
3. As previously expected, K2M anticipates the merger will close in the fourth quarter of this year, pending the completion of other customary closing conditions.
4. When the merger is complete, K2M stockholders will receive $27.50 in cash per share.
5. The Federal Trade Commission extended the anti-trust deadline for Stryker to Nov. 16.
More articles on orthopedic devices:
DePuy Synthes to outsource production, closes manufacturing plant: 5 things to know
Joimax moves into bigger US headquarters: 5 things to know
Biologics in thefuture for RTI Surgical—5 key quotes from CEO Camille Farhat